Short-term outcomes, longer-term disability and relapse risk in LGI1-antibody encephalitis
Sudarshini Ramanathan, John Soltys, Sophia Michael, Samuel V Mackrill, Jonathan Cleaver, Robyn Williams, Mateusz Makuch, Patrick Waters, Yaacov Ansizka, Alessandro Dinoto, Mohsen Farazdaghi, Benjamin Trewin, Jan Rudnik, Panayotes Demakakos, Stephen Yates, Anais Thouin, Sonam Dilwali, Hyoshin Son, Russell C Dale, Anu Jacob, Andreas Lutterotti, Ava Easton, Adam E Handel, Michael D Geschwind, Jeffrey M Gelfand, Soon-Tae Lee, Carsten Finke, Sophie Binks, Tomas Kalincik, Sarosh R Irani, , Julia Thompson, Mian Bi, Todd A Hardy, Ming Wei Lin, Sanjay Swaminathan, Andrew Bleasel, Stephen W Reddel, Michael Johnson, Isabel Leite, Paul Maddison, Jan Coebergh, Saiju JacobAbstract
Leucine-rich glioma-inactivated-1 antibody encephalitis (LGI1-Ab-E) is a common and immunotherapy-responsive form of encephalitis. However, it is not known which immunotherapy regimens improve short-term outcomes, longer-term disability and relapse risk. Further, it is not known if the widely-utilised modified Rankin Scale (mRS) accurately captures quality of life (QoL) in LGI1-Ab-E, complicating disability measurements and interpretation of immunotherapy responses.
A multicentre, international, real-world comparative analysis of patients with LGI1-Ab-E. Retrospective data from patient records evaluated short-term seizure and cognitive outcomes, 1-6 year disability, and future relapse risk associations, by integrating demographics, clinical features investigations and exposures to immunotherapies and antiseizure medications (ASMs). Patient- and neurologist-rated QoL assessments were used to establish an evidence-based mRS threshold for defining clinically significant disability. Cox proportional hazard models, Anderson-Gill, and generalised linear mixed-effects models were employed.
181 patients were included, with median age at onset 63 years (range 23 - 92); 122/181 (67%) were male. Short-term outcomes, evaluated at both five and ten weeks post-treatment initiation, identified exposure to immunotherapies associated with seizure resolution (OR = 13.97, 95%CI = 6.10-32.01; p < 0.0001 and OR = 8.53, 95%CI = 4.14-17.55; p < 0.0001, respectively), notably with corticosteroids, plasma exchange and rituximab, but not ASMs, intravenous immunoglobulins or steroid sparing agents. Conversely, seizure recurrence was observed after discontinuation of oral prednisolone, but not other immunotherapies or ASMs (OR = 39.53, 95%CI = 12.70-122.20, p < 0.0001). To evaluate longer-term disability, first, mRS scores were calibrated using QoL assessments: this identified a significant increase in patient-rated disability at mRS score of 2. Hence, using mRS 0-1 as a favourable outcome, we identified worse mRS at nadir associated with greater one-year disability (OR = 2.56, 95%CI = 1.56–4.20, p = 0.0003), and each month of delayed immunotherapy associated with a 16% increased risk of disability (HR = 1.16, 95%CI = 1.06-1.35, p = 0.004). Additionally, absence of immunotherapy associated both with greater one-year disability (OR = 5.67; 95% CI 1.19-26.54, p = 0.03) and a relapsing course (OR = 7.64, 95%CI = 2.51-21.77, p = 0.0002). Both a relapsing course, observed in 38% of patients, and the number of relapses associated with step-wise worsening of disability and QoL-outcomes. Rituximab exposure was the only identified clinical factor associated with reduced future relapse risk, by 93% (HR = 0.07, 95%CI = 0.01-0.48, p = 0.002). Persistent serum LGI1-IgMs, but not LGI1-IgGs, at one-year, associated with future relapses (HR = 11.69, 95%CI = 1.58-145.80, p = 0.02).
Distinctive clinical factors and select immunotherapies, particularly intravenous methylprednisolone and plasma exchange, but not ASMs, associated with favourable short-term outcomes, patient-centric longer-term disability and relapses in LGI1-Ab-E. Our findings provide evidence-based disability thresholds, highlight novel prognostic biomarkers, and pragmatically guide LGI1-Ab-E care, pending randomized clinical trials.